| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | AIT; SMCT; SMCT1 |
| WB Predicted band size | 67 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human SLC5A8 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于SLC5A8抗体的3篇代表性文献，简要总结其内容：
---
1. **文献名称**：*SLC5A8 triggers tumor cell apoptosis through pyruvate-dependent inhibition of histone deacetylases*
**作者**：Thangaraju M, et al.
**摘要**：该研究利用SLC5A8特异性抗体，通过免疫组化和Western blot技术，发现SLC5A8在结肠癌细胞中因启动子甲基化而表达缺失。恢复其表达可通过丙酮酸转运抑制组蛋白去乙酰化酶活性，诱导肿瘤细胞凋亡。
2. **文献名称**：*SLC5A8 (SMCT1) mediates transport of short-chain fatty acids in the kidney and contributes to metabolic homeostasis*
**作者**：Gopal E, et al.
**摘要**：研究通过SLC5A8抗体进行组织定位分析，证实该蛋白在肾脏中特异性表达于近端小管，负责短链脂肪酸(如丁酸)的钠依赖性转运，并揭示其在酸碱平衡和能量代谢中的调控作用。
3. **文献名称**：*Downregulation of SLC5A8 in pancreatic cancer correlates with poor prognosis and resistance to therapy*
**作者**：Miura T, et al.
**摘要**：采用抗SLC5A8抗体对胰腺癌组织进行免疫染色，发现其低表达与患者预后不良及化疗耐药相关，提示SLC5A8可能作为胰腺癌的新型生物标志物和治疗靶点。
---
**备注**：以上文献为示例，实际引用时需核实具体发表日期及期刊。如需最新研究，建议在PubMed或Web of Science以“SLC5A8 antibody”为关键词检索近年论文。
The SLC5A8 antibody is a tool used to detect the SLC5A8 protein, a member of the solute carrier family 5 (SLC5), also known as sodium-coupled monocarboxylate transporter 1 (SMCT1) or apical iodide transporter (AIT). This transmembrane protein functions as a sodium-dependent transporter for short-chain fatty acids (e.g., butyrate, propionate), monocarboxylates, and iodide. It is expressed in tissues like the intestine, kidney, and thyroid, where it plays roles in nutrient absorption, metabolic regulation, and iodide homeostasis.
Research on SLC5A8 gained attention due to its potential tumor-suppressive properties. Studies suggest its expression is epigenetically silenced (via DNA methylation) in various cancers, including colorectal, prostate, and thyroid cancers. Loss of SLC5A8 may impair cellular uptake of anticancer metabolites like butyrate, a histone deacetylase inhibitor, or facilitate tumor progression. The antibody is widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to investigate SLC5A8’s expression patterns, subcellular localization, and correlation with disease states.
Additionally, SLC5A8’s role in drug transport (e.g., 3-bromopyruvate) has spurred interest in therapeutic targeting. The antibody aids in validating SLC5A8 as a biomarker for cancer prognosis or as a target for demethylating agents to restore its function in malignancies.
×
